Cancer Stromal Targeting

DOI Web Site 23 References
  • Yasunaga Masahiro
    Division of Developmental Therapeutics, Center of Innovative Oncology, National Cancer Center Hospital East
  • Manabe Shino
    RIKEN, Synthetic Cellular Chemistry Laboratory
  • Matsumura Yasuhiro
    Division of Developmental Therapeutics, Center of Innovative Oncology, National Cancer Center Hospital East

Bibliographic Information

Other Title
  • がん間質ターゲット
  • ガン カンシツ ターゲット

Search this article

Description

Antibody-drug conjugate (ADC) targeting tumor cells themselves was effective for hematological malignancy or breast cancer having hyper- vascularity and poor stroma. However, it was not effective for the refractory tumors such as brain tumor, scirrhous gastric cancer or pancreatic cancer. Dense stroma prevents the ADC form reaching the tumor cells within the tumor tissues. To overcome "stromal barrier", we created "CAST (Cancer stromal targeting) therapy" using ADC targeting to a tumor stroma. We have succeeded in developing anti-cancer agent (SN-38) conjugated anti-collagen 4 antibody or anti-fibrin antibody. The therapy damaged both tumor cells and tumor vasculature. Bone marrow toxicity, hepatorenal disorder or autonomatous harmful immune response was not recognized. Further evaluation of the CAST therapy is necessary for a future clinical application.

Journal

  • Drug Delivery System

    Drug Delivery System 28 (5), 396-405, 2013

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(23)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top